DENVER, Oct. 3, 2018 /PRNewswire/ -- DaVita
Inc.(NYSE: DVA), a health care services provider of kidney care,
clinical research and care to the chronically ill, today
acknowledged its collective achievements in improving clinical
outcomes and research so far in 2018.
"Delivering differential care for medically-complex patient
populations is a core competency at DaVita," said Allen R. Nissenson, M.D., FACP, chief medical
officer for DaVita Kidney Care.
"We've made great strides in consistently providing quality patient
care and impactful research this year, and we look forward to
building on this success."
DaVita® Health Solutions
DaVita Health Solutions, a subsidiary of DaVita Inc., delivers
house calls and post-acute care programs to help manage the
nation's most high-risk patients—or Most Vulnerable Patients
(MVPs)—under at-risk arrangements with payer and risk-bearing
entities. The company recently partnered with a large regional
health plan to help manage its MVPs who initially had:
- Four or more chronic conditions per patient
- 800 emergency department visits per 1,000 patients
- 650 hospital admits per 1,000 patients
The program served approximately 7,000 patients in partnership
with over 600 local primary care physicians, specialists and
extended care teams, including family members, caregivers,
hospitals, skilled nursing facilities and home care agencies.
By the end of year one, DaVita Health Solutions made a positive
impact:
- 10-15 percent fewer emergency room visits
- 35-40 percent fewer hospitalizations
- 15-20 percent lower cost of care
- 91 percent patient satisfaction rating
To learn more about DaVita Health Solutions program and results,
download the case study.
DaVita Kidney Care
This year, the Centers for Medicare & Medicaid Services
(CMS) released results for its two clinical quality programs for
the kidney care industry, each of which indicates DaVita Kidney Care as a clinical quality
leader.
Quality Incentive Program Results
CMS' end stage renal disease (ESRD) Quality Incentive
Program (QIP) results showed DaVita's was one of the best
clinical quality providers. The entire kidney care community
improved key clinical outcome metrics this year, including:
- Central venous catheters, a common but least desirable
form of blood access for dialysis treatments, were reduced by 18
percent.
- Infection rates decreased by 14 percent. ESRD
patients have impaired immune systems as well as co-morbid
conditions, such as diabetes, that makes them particularly
susceptible to infections.
- Dialysis adequacy, the measure that tells clinicians how
well dialysis is working to remove waste products from the blood,
was improved by 5 percent.
Five-Star Quality Rating System (Five-Star) Results
DaVita's focus on helping improve patients' health and quality
of life is demonstrated in this year's Five-Star ratings, where the
company has more three, four and five star centers than it has ever
had in the history of the program. The results mark DaVita's best
quality performance in the program to date.
The broader kidney care community has also continued to improve
with an increase in the number of dialysis centers receiving a
three-, four- or five-star quality rating by 10 percent since 2016.
Other meaningful improvements have been demonstrated in publicly
reported clinical quality measures, including:
- 3 percent improvement in dialysis adequacy, which measures how
well dialysis removes waste from the blood.
- 8 percent improvement in bloodstream infections, which are one
of the leading causes of hospitalizations among dialysis
patients.
DaVita Clinical Research
DaVita Clinical Research (DCR), the research arm of DaVita that
informs clinical care and outcomes through retrospective
research. DCR also delivers new therapies with a renal
research site network that assists pharmaceutical and medical
device companies in the design, recruitment and completion of
clinical trials. DCR has furthered nephrology practice and
contributed to its body of knowledge by publishing these research
results in 2018.
Printed Manuscripts
- Effects of Oral Nutritional Supplements on Mortality, Missed
Dialysis Treatments, and Nutritional Markers in Hemodialysis
Patients. J Ren Nutr. 2018;28(3):191-6. Epub 2017/12/10.
DCR analysis of DaVita pilot program to provide ONS to in-center
hemodialysis patients with serum albumin ≤ 3.5 g/dL; demonstrated
beneficial effects of ONS in reducing mortality.
- The Precision of Standardized Hospitalization, Readmission, and
Mortality Ratios for Dialysis Facilities. Am J Kidney Dis.
2018;71(2):291-4. Epub 2017/11/23.
DCR analysis to assess the precision of standardized ratios
(SHR, SMR, SRR) as applied to dialysis facilities: results
demonstrate that, as currently calculated, standardized ratios are
highly imprecise, limiting their utility for comparing dialysis
facility performance.
- Dialysate temperature of 36 degrees C: association with
clinical outcomes. J Nephrol. 2018;31(1):129-36. Epub
2016/12/22.
DCR study assessing whether standardized dialysate temperature
of 36C was associated with improved clinical outcomes compared to
the default temperature of 37C: results showed that rates of death,
hospitalization, missed treatments and intradialytic hypotension
were not significantly different between groups.
- Vocational activity and health insurance type among patients
with end-stage renal disease: association with outcomes. J
Nephrol. 2018;31(4):577-84. Epub 2018/02/09.
DCR study showing that vocational activity and, separately,
commercial insurance were independently associated with better
clinical and quality of life outcomes compared to other vocational
and insurance status categories.
- Serum-to-dialysate potassium gradient and its association with
short-term outcomes in hemodialysis patients. Nephrol Dial
Transplant. 2018;33(7):1207-14. Epub 2017/10/11.
High serum to dialysate potassium gradient at the start of
dialysis leads to rapid lowering of serum potassium. In this study,
higher potassium gradient was shown to be independently associated
with greater risk for all-cause hospitalization and ED
visits.
- Cluster-Randomized Trial of Devices to Prevent Catheter-Related
Bloodstream Infection. J Am Soc Nephrol. 2018;29(4):1336-43.
Epub 2018/02/24.
Prospective, cluster-randomized, open-label trial showed that,
compared to Tego hemodialysis connectors with Curos disinfecting
caps, ClearGuard HD antimicrobial barrier caps significantly
lowered the rate of catheter-related BSIs in patients undergoing
dialysis using CVCs.
- Anemia and mortality in patients with nondialysis-dependent
chronic kidney disease. BMC Nephrol. 2018;19(1):135. Epub
2018/06/13.
DCR study evaluating contemporary use of
erythropoiesis-stimulating agents in patients with pre-dialysis
CKD: ESA use in pre-dialysis CKD patients was extremely rare and
disproportionately among older, sicker patients who had high rates
of death and cardiovascular events.
Conference Publications
- Pharmacokinetics, Safety, and Tolerability of Thrice-Weekly
Dosing of Cinacalcet in Hemodialysis Patients with Secondary
Hyperparathyroidism (SHPT). Poster presented at 2018 National
Kidney Foundation Spring Clinical Meetings. April 10-14, 2018; Austin, TX.
Phase I, open-label, multiple dose study to assess the
pharmacokinetics, safety and tolerability of thrice-weekly
cinacalcet in hemodialysis patients with secondary
hyperparathyroidism; study results suggested that thrice weekly
administration was safe and effective and may therefore offer an
alternative to current clinical practice.
About DaVita Inc.
DaVita Inc., a Fortune 500® company,
is the parent company of DaVita Kidney Care and DaVita
Medical Group. DaVita Kidney Care is a leading provider
of kidney care in the United
States, delivering dialysis services to patients with
chronic kidney failure and end stage renal disease. As of June
30, 2018, DaVita Kidney Care operated or provided
administrative services at 2,580 outpatient dialysis centers
located in the United States serving approximately
201,000 patients. The company also operated 253 outpatient dialysis
centers located in 10 countries outside the United States. DaVita Medical Group manages
and operates medical groups and affiliated physician networks
in California, Colorado, Florida, Nevada, New
Mexico and Washington in its pursuit to deliver
excellent-quality health care in a dignified and compassionate
manner. DaVita Medical Group's teammates, employed clinicians and
affiliated clinicians provided care for approximately 1.7 million
patients. For more information, please
visit DaVita.com/About.
Contact Information
Halie Peddle
Halie.Peddle@DaVita.com
720.631.1226
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delivering-quality-care-and-innovation-where-it-matters-most-300723266.html
SOURCE DaVita Inc.